The patent relates to the manufacturing process for the active ingredient in Sanofi-Aventis' Allegra and Allegra-D drug products. Both Dr Reddys and Sandoz are known to be marketing these products in the US.
"We believe this patent infringement filing strengthens our litigation strategy on Allegra, Allegra D-12 and Allegra D-24 against these generic drug companies in the US and other jurisdictions. Amri remains committed to vigorously protecting and enforcing its intellectual property," said Amri chairman, president and CEO Thomas E D'Ambra in a press release said.